Press release
2018-05-24
Your integrity is important to us
Xbrane protects our stakeholder's personal integrity. To give you a better understanding of how we handle your personal information, we have updated our privacy policy in accordance with the new EU Directive, the General Data Protection Regulation (GDPR).
The new policy is valid as of May 25, 2018 and will have a positive effect on your personal integrity and change how we as a company collect and process your personal information. Something we do to make our communication as relevant as possible. By continuing to use Xbrane's newsletter, you agree to the new terms.
Xbrane's privacy policy is available at the Company's website, read more here.
About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long-acting injectables. Xbrane has world leading expertise in developing generics for long-acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbrane's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser. For more information see www.xbrane.com.
For further information, please contact:
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com
Susanna Helgesen
CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com
